Abaktal (pefloxacin) ampoules 400 mg. 5 ml. №10

Code ATX: J01MA03

Pharmacodynamics

Pefloxacin is a synthetic antimicrobial drug from the group of fluoroquinolones. Acts bactericidally, inhibiting the enzyme DNA gyrase and replication of bacterial DNA; it also disrupts the replication of the A-subunit of ribonucleic acid and the synthesis of proteins by a bacterial cell. In relation to gram-negative bacteria, it acts on cells that are both in the resting phase and in the phase of division, in relation to gram-positive bacteria – only on cells that are in the process of mitotic division. Postantibiotic effect is characteristic.

Pefloxacin has a wide spectrum of antimicrobial action.

The following microorganisms are sensitive to pefloxacin: Aeromonas hydrophila, Campylobacter jejuni, Citrobacter spp., Enterobacter spp., Escherichia coli, Haemophilus ducreyi, Haemophilus influenzae, Klebsiella spp., Legionella pneumophila, Moraxella catarrhalis, Morganella morganii, Pasteurella multocida, Proteus mirabilis, indol- positive Proteus, Providencia stuartii, Salmonella spp., Serratia spp., Shigella spp., Vibrio cholerae.

Moderate sensitivity to the drug has: Streptococcus spp., except Streptococcus pneumoniae; Acinetobacter spp., Neisseria gonorrhoeae, Neisseria meningitidis, Staphylococcus aureus, Chlamydia trachomatis.

The following are resistant: Clostridium perfringens, Enterococcus spp., Gardnerella vaginalis, gram-negative anaerobic microorganisms, spirochetes (Treponema spp., Borrelia spp., Leptospira spp.), Pseudomonas aeruginosa, Mycoplasma spp, Ureaplasma urealyticum and Mycobacterium tuberculosis.

Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to pefloxacin:

• complicated urinary tract infections;
• bacterial prostatitis;
• lower respiratory tract infections (exacerbation of cystic fibrosis, nosocomial pneumonia);
• infections of the organs of the abdominal cavity and the hepatobiliary system;
• bacterial infections of the gastrointestinal tract with severe course, including salmonellosis;
• bone and joint infections (osteomyelitis caused by gram-negative microorganisms);
• skin and soft tissue infections;
• bacterial endocarditis;
• meningitis (if the causative agent is sensitive only to pefloxacin);
• gonorrhea.

For the treatment of the following infectious and inflammatory diseases, pefloxacin can be used only as an alternative to other antimicrobial drugs:

• acute sinusitis;
• exacerbation of chronic bronchitis;
• uncomplicated urinary tract infections.

Pefloxacin is used as monotherapy or in the form of combined therapy with other antimicrobial agents.
Pefloxacin is effective in the treatment and prevention of infections in immunocompromised patients.
It is necessary to take into account the current official guidelines on the rules for the use of antibacterial agents.

Pefloxacin penetrates into breast milk in large quantities (75% of the serum concentration). Therefore, it is necessary to stop breastfeeding while using the drug.

• increased sensitivity to fluoroquinolones and/or to other components of the drug;
• lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;
• severe liver function disorders;
• deficiency of glucose-6-phosphate dehydrogenase;
• tendon lesions in the anamnesis, which occurred during previous treatment with fluoroquinolones;
• children’s age up to 18 years (due to the risk of severe forms of arthropathy, especially large joints);
• pregnancy and the period of breastfeeding.